We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Just in time for allergy season, the FDA granted fast-track status to Accentia’s drug SinuNase, a treatment for chronic sinusitis (CS), the company said April 12.